Stoke Therapeutics Inc (STOK)
14.61
+0.83
(+6.02%)
USD |
NASDAQ |
May 31, 16:00
14.61
0.00 (0.00%)
After-Hours: 20:00
Stoke Therapeutics Enterprise Value: 582.89M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 582.89M |
| May 30, 2024 | 539.63M |
| May 29, 2024 | 539.11M |
| May 28, 2024 | 554.49M |
| May 24, 2024 | 572.47M |
| May 23, 2024 | 588.10M |
| May 22, 2024 | 645.43M |
| May 21, 2024 | 621.46M |
| May 20, 2024 | 660.55M |
| May 17, 2024 | 545.89M |
| May 16, 2024 | 552.66M |
| May 15, 2024 | 557.87M |
| May 14, 2024 | 488.55M |
| May 13, 2024 | 423.40M |
| May 10, 2024 | 419.76M |
| May 09, 2024 | 447.38M |
| May 08, 2024 | 426.01M |
| May 07, 2024 | 443.73M |
| May 06, 2024 | 440.08M |
| May 03, 2024 | 447.90M |
| May 02, 2024 | 430.70M |
| May 01, 2024 | 423.92M |
| April 30, 2024 | 396.30M |
| April 29, 2024 | 439.56M |
| April 26, 2024 | 468.20M |
| Date | Value |
|---|---|
| April 25, 2024 | 430.67M |
| April 24, 2024 | 429.11M |
| April 23, 2024 | 407.74M |
| April 22, 2024 | 407.74M |
| April 19, 2024 | 449.43M |
| April 18, 2024 | 428.59M |
| April 17, 2024 | 432.24M |
| April 16, 2024 | 470.28M |
| April 15, 2024 | 457.77M |
| April 12, 2024 | 486.96M |
| April 11, 2024 | 525.01M |
| April 10, 2024 | 486.44M |
| April 09, 2024 | 491.13M |
| April 08, 2024 | 498.95M |
| April 05, 2024 | 473.29M |
| April 04, 2024 | 452.55M |
| April 03, 2024 | 486.00M |
| April 02, 2024 | 499.74M |
| April 01, 2024 | 448.68M |
| March 31, 2024 | 449.14M |
| March 28, 2024 | 423.71M |
| March 27, 2024 | 454.73M |
| March 26, 2024 | 275.07M |
| March 25, 2024 | 99.58M |
| March 22, 2024 | 90.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-65.45M
Minimum
Oct 27 2023
2.266B
Maximum
Jan 19 2021
557.03M
Average
514.81M
Median
Mar 30 2020
Enterprise Value Benchmarks
| NeuBase Therapeutics Inc | -- |
| iBio Inc | 28.91M |
| Lixte Biotechnology Holdings Inc | 5.345M |
| Fate Therapeutics Inc | 35.36M |
| Ocular Therapeutix Inc | 466.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.37M |
| Revenue (Quarterly) | 4.216M |
| Total Expenses (Quarterly) | 32.59M |
| EPS Diluted (Quarterly) | -0.57 |
| Profit Margin (Quarterly) | -625.6% |
| Earnings Yield | -16.50% |
| Normalized Earnings Yield | -16.50 |